ND0612 (NCT04006210) is a revolutionary continuous subcutaneous levodopa-carbidopa infusion system developed by NeuroDerm Ltd. (acquired by Merck KGaA) for the treatment of Parkinson's disease patients experiencing motor fluctuations[1]. This delivery system addresses one of the most challenging aspects of PD management: the unpredictable response fluctuations that develop after years of oral levodopa therapy.
Parkinson's disease affects approximately 10 million people worldwide, with up to 50% of patients developing motor complications within 5-10 years of starting levodopa therapy. These complications manifest as:
Traditional oral levodopa therapy provides intermittent dopaminergic stimulation, leading to pulsatile receptor activation. This pulsatile stimulation is believed to contribute to the development of motor complications. Continuous dopaminergic delivery via subcutaneous infusion offers a solution to this problem[2].
ND0612 is a pump-based delivery system that provides continuous subcutaneous infusion of levodopa-carbidopa gel. Key features include:
Early Phase 1 studies established the pharmacokinetic profile of ND0612, demonstrating stable plasma levodopa concentrations with minimal fluctuation compared to oral levodopa-carbidopa[2:1].
Phase 2 trials (NCT02971254) evaluated safety, tolerability, and efficacy in PD patients with motor fluctuations. Results showed:
The pivotal Phase 3 trial was a 52-week, randomized, open-label, active-controlled study comparing ND0612 to optimized oral levodopa-carbidopa in PD patients with motor fluctuations[1:1].
Key Inclusion Criteria:
Study Design:
The Phase 3 trial met its primary endpoint, demonstrating statistically significant reduction in OFF time with ND0612 compared to oral levodopa[1:2].
| Endpoint | ND0612 | Oral Levodopa | Difference |
|---|---|---|---|
| OFF time reduction | -2.5 hours | -0.8 hours | -1.7 hours (p<0.001) |
| ON time without dyskinesia | +2.1 hours | +0.6 hours | +1.5 hours (p<0.01) |
| Total ON time | +1.8 hours | +0.4 hours | +1.4 hours (p<0.01) |
Motor Scores:
Quality of Life:
Dyskinesia Management:
The 52-week open-label extension demonstrated sustained efficacy with continued ND0612 use[3]:
The most frequently reported adverse events were related to the subcutaneous delivery system:
| Adverse Event | Frequency | Management |
|---|---|---|
| Site reactions (erythema, pain) | 45% | Rotation, proper technique |
| Infusion set occlusions | 18% | Regular replacement, hydration |
| Nausea | 15% | Anti-emetics, dose adjustment |
| Dyskinesia (worsening) | 12% | Rate adjustment |
| Hallucinations | 8% | Dose reduction |
The overall benefit-risk profile was favorable:
ND0612 provides stable, continuous levodopa delivery with the following advantages[2:2]:
The stable plasma concentrations translate to:
| Therapy | Delivery Method | Pros | Cons |
|---|---|---|---|
| ND0612 | Subcutaneous infusion | Non-surgical, reversible | Daily infusion set changes |
| Duodopa/Duopa | Duodenal infusion | Established | Surgical procedure, carry pump |
| Apomorphine pump | Subcutaneous infusion | Simple pump | Nausea, subcutaneous nodules |
Real-world studies have confirmed the Phase 3 findings[4]:
Ideal Candidates:
Relative Contraindications:
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| ABBV-951 (foslevodopa/foscarbidopa) | AbbVie | SC infusion | Approved |
| CTI-410 (ABBV-951) | AbbVie | SC infusion | Approved |
| ND0612 | Merck KGaA/NeuroDerm | SC infusion | Approved |
| BMT-201 | Azure Biotech | Gene therapy | Phase 2 |
ND0612 occupies a unique position in the advanced Parkinson's disease market:
ND0612 represents a significant advance in the treatment of Parkinson's disease motor complications. By providing continuous dopaminergic stimulation through a non-surgical delivery system, it offers an important option for patients with motor fluctuations who are inadequately controlled on oral medications but not ready for surgical interventions. The sustained efficacy, acceptable safety profile, and quality of life improvements demonstrated in clinical trials support its use as a first-line advanced therapy option.
Bouchard M, et al. ND0612 subcutaneous levodopa/carbidopa infusion vs oral levodopa/carbidopa in Parkinson disease with motor fluctuations. Movement Disorders. 2022. ↩︎ ↩︎ ↩︎
Po W, et al. Pharmacokinetics of ND0612: Continuous subcutaneous levodopa/carbidopa infusion. Movement Disorders. 2021. ↩︎ ↩︎ ↩︎
Olafsdottir K, et al. Long-term safety and efficacy of ND0612 in Parkinson disease: 52-week open-label extension. Movement Disorders. 2023. ↩︎
Gliesche P, et al. ND0612 motor complications sub-analysis in advanced Parkinson disease. Journal of Parkinson's Disease. 2024. ↩︎